anti-cancer drug, *e.g.*, a chemotherapeutic agent; an anti-inflammatory agent, *e.g.*, nitric oxide, mannitol, allopurinol, or dimethyl sulfoxide; an anti-depressant; or a cholinesterase inhibitor.--

A1

In the claims:

Please cancel claims 1-23 and 33-65, without prejudice, and amend claims 24 and 25 as follows:

24. **(Amended)** A method for enhancing the bioavailability of a β-amyloid peptide derivative to the brain of a subject, comprising administering to the subject the β-amyloid peptide derivative and a P-glycoprotein inhibitor, wherein said P-glycoprotein inhibitor and said β-amyloid polypeptide derivative are separate chemically distinct compounds and wherein said P-glycoprotein inhibitor is not a liposome or Tween-80, thereby enhancing the bioavailability of the β-amyloid peptide derivative to the brain of the subject.

A2

25. **(Amended)** The method of claim 24, wherein the β-amyloid peptide derivative is selected from the group consisting of PPI-558, PPI-657, PPI-1019, PPI-578, and PPI-655.

REMARKS

Claims 1-65 were pending in the application. Claims 1-23, 33-46, and 48-65 have been cancelled, without prejudice, as being directed to a non-elect invention. Claim 47 has also been cancelled, without prejudice, and claims 24 and 25 have been amended. Accordingly, after the amendments presented herein have been entered, claims 24-32 will remain pending. For the Examiner's convenience all of the pending claims are set forth herein in Appendix A.

Attached hereto is a marked-up version of the changes made to the claims by the current amendments. The attached page is captioned "**Version With Markings to Show Changes Made.**"